Published on 02/12/2025

Auditing Contract Manufacturers for SUS Controls

As the pharmaceutical industry increasingly relies on contract manufacturers for single-use systems (SUS), it becomes paramount to ensure that these partnerships maintain the highest standards of quality and compliance. This article outlines a detailed, step-by-step guide for auditing contract manufacturers specifically focusing on extractables and leachables (E&L) controls, analytical evaluation thresholds (AET), dose-based thresholds (DBT), and container closure integrity (CCI), in accordance with regulatory requirements set forth by governing bodies like the FDA, EMA, and MHRA.

Understanding the Importance of E&L in SUS

Contract manufacturers play a critical role in the production of pharmaceutical products, especially those utilizing single-use systems. These systems often include filters, bags, and other components that can potentially introduce contaminants, both from the manufacturing process and the materials themselves. Understanding the implications of E&L is essential for ensuring patient safety and product efficacy.

With the implementation of USP CCI guidelines, it is vital for pharmaceutical companies to have a robust E&L risk assessment strategy that evaluates potential extractables and leachables from the materials used in SUS. These contaminants can arise from various sources, including:

• Raw materials used in the manufacture of containers and closures
• Processing conditions, such as exposure to heat and solvent interactions
• Leachables that can migrate into the drug product under normal storage and use conditions

E&L assessments not only support regulatory compliance but also protect the integrity of the drug product and the health of patients. Therefore, embarking on an audit of contract manufacturers necessitates a structured approach toward assessing these risks comprehensively.

Preparation for an Effective Audit

The preparation phase is crucial in ensuring that the audit of the contract manufacturer is comprehensive and effective. Here’s how to prepare:

1. Define the Scope of the Audit: Identify and document the specific processes and systems to be audited, including the types of filters and bags. Clearly outline the materials and suppliers involved.
2. Gather Relevant Documentation: Request documentation such as the E&L study reports, the supplier’s validation data, and historical compliance records. This should include previous audit reports, change control forms, and any deviations noted.
3. Set Criteria for Evaluation: Establish a benchmark against which the audit will be assessed, focusing on E&L risk assessments, AET/DBT calculations, and adherence to EU GMP Annex 1.

Conducting the Audit

Conducting an audit involves several key steps that should be meticulously followed:

1. Initial Meeting with the Manufacturer: Start the audit with an opening meeting to discuss the audit’s scope, objectives, and timeframe. This is also an opportunity to assess the manufacturer’s knowledge of E&L requirements.
2. Facility Inspection: Perform a walkthrough of the production facilities, focusing on areas related to single-use systems. Assess cleanliness, equipment calibration, and personnel practices.
3. Review E&L Risk Assessments: Ensure that the contract manufacturer has conducted thorough E&L assessments. Examine whether they follow established protocols and methodologies for risk evaluation, and check if the AET/DBT calculations are documented appropriately.
4. Examine Analytical Data: Review analytical reports related to E&L studies. Confirm that performed tests adhere to recognized standards and include assessments for potential leachable compounds.
5. Assess Quality Management Systems (QMS): Evaluate the contract manufacturer’s QMS, including how they document changes, deviations, and corrective actions associated with E&L controls.

Post-Audit Actions

After completing the audit, it is essential to follow through with a structured post-audit process that can include:

1. Document Findings: Prepare a comprehensive audit report that documents all findings, including observed deviations, strengths, and areas for improvement. Reference specific data and observations taken during the audit.
2. Conduct a Closing Meeting: Hold a meeting with the manufacturer to discuss audit findings. This should provide a platform for both parties to address any concerns highlighted during the audit.
3. Action Plan Development: Collaborate with the contract manufacturer to develop an action plan to resolve any identified issues. Ensure timelines are established and assign responsibilities for follow-up actions.
4. Follow Up: Schedule follow-up audits or reviews to ensure that identified actions have been completed satisfactorily. Continuous monitoring is essential to maintaining compliance.

Regulatory Considerations

Understanding regulatory requirements is crucial for both pharma companies and their contract manufacturers. Compliance with guidelines issued by authorities such as the PIC/S ensures products meet both safety and quality standards. Key considerations include:

• E&L Regulatory Guidelines: Familiarize yourself with industry guidelines such as the PQRI guidance on E&L. This can help shape your audit checklist and evaluation criteria.
• Documentation and Record-Keeping: Regulatory agencies require comprehensive documentation of all processes, including E&L testing, process validations, and any corrective actions taken. Review the manufacturer’s system for tracking documentation.
• Training and Competency: Ensure that personnel involved in the processes have received adequate training and are competent in their roles, specifically regarding E&L and E&L risk assessment.

Implementing Continuous Improvement

Auditing is not a one-off activity but part of a continual improvement process. After each audit, introduce methods to enhance the efficiency and effectiveness of the contract manufacturer’s processes:

1. Set Key Performance Indicators (KPIs): Develop KPIs that measure the effectiveness of E&L controls and compliance, tracking progress over time.
2. Engage in Regular Reviews: Establish regular progress reviews with the contract manufacturer to maintain ongoing communication about E&L initiatives.
3. Adapt to Changes: Continually adapt audit processes and criteria to reflect changes in regulations, technology advancements, and the evolving landscape of E&L challenges.

By implementing these practices, companies can help ensure that they and their contract manufacturers maintain the standards necessary for regulatory compliance and patient safety.

Conclusion

Auditing contract manufacturers for SUS controls is a crucial undertaking in the pharmaceutical industry. A well-structured audit not only ensures compliance with regulatory standards but also safeguards product integrity and patient health. By focusing on E&L risk assessments, AET/DBT calculations, and CCI, companies can effectively reduce risks associated with single-use systems. Continuous improvement in these areas will enhance both operational efficiency and alignment with regulatory expectations, ultimately fortifying the supply chain in the pharmaceutical sector.